[1]
Minn AH, Kayton M, Lorang D, Hoffmann SC, Harlan DM, Libutti SK, Shalev A. Insulinomas and expression of an insulin splice variant. Lancet (London, England). 2004 Jan 31:363(9406):363-7
[PubMed PMID: 15070567]
[2]
Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future oncology (London, England). 2010 Feb:6(2):229-37. doi: 10.2217/fon.09.165. Epub
[PubMed PMID: 20146582]
[3]
Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clinic proceedings. 1991 Jul:66(7):711-9
[PubMed PMID: 1677058]
[4]
Salazar R, Wiedenmann B, Rindi G, Ruszniewski P. ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: an update. Neuroendocrinology. 2012:95(2):71-3. doi: 10.1159/000335600. Epub 2012 Feb 15
[PubMed PMID: 22262042]
Level 3 (low-level) evidence
[5]
Placzkowski KA,Vella A,Thompson GB,Grant CS,Reading CC,Charboneau JW,Andrews JC,Lloyd RV,Service FJ, Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. The Journal of clinical endocrinology and metabolism. 2009 Apr;
[PubMed PMID: 19141587]
[6]
Pratò S, Didonna V, Garletti F, Marfia G, Barbaresi A, Palumbo F, Garzia E, Ciniglio Appiani G, Riboldi L, Vigna L. Loss of consciousness in a helicopter pilot as plausible first sign of insulinoma: a case report. La Medicina del lavoro. 2022 Feb 22:113(1):e2022007. doi: 10.23749/mdl.v113i1.12037. Epub 2022 Feb 22
[PubMed PMID: 35226655]
Level 3 (low-level) evidence
[7]
Karanth JB, Pai V, Maribashetti K. Pancreatic neuroendocrine tumour-insulinoma masquerading as a psychiatric illness. BMJ case reports. 2022 Jun 14:15(6):. doi: 10.1136/bcr-2022-249698. Epub 2022 Jun 14
[PubMed PMID: 35701018]
Level 3 (low-level) evidence
[8]
Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL, North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010 Aug:39(6):713-34. doi: 10.1097/MPA.0b013e3181ebaffd. Epub
[PubMed PMID: 20664471]
Level 3 (low-level) evidence
[9]
Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ, Endocrine Society. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2009 Mar:94(3):709-28. doi: 10.1210/jc.2008-1410. Epub 2008 Dec 16
[PubMed PMID: 19088155]
Level 1 (high-level) evidence
[10]
ASGE Standards of Practice Committee, Eloubeidi MA, Decker GA, Chandrasekhara V, Chathadi KV, Early DS, Evans JA, Fanelli RD, Fisher DA, Foley K, Hwang JH, Jue TL, Lightdale JR, Pasha SF, Saltzman JR, Sharaf R, Shergill AK, Cash BD, DeWitt JM. The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia. Gastrointestinal endoscopy. 2016 Jan:83(1):17-28. doi: 10.1016/j.gie.2015.09.009. Epub
[PubMed PMID: 26706297]
[11]
Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best practice & research. Clinical endocrinology & metabolism. 2005 Jun:19(2):213-27
[PubMed PMID: 15763696]
[12]
Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, Gloor B, Martius F, Maecke H, Reubi JC. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. The Journal of clinical endocrinology and metabolism. 2009 Nov:94(11):4398-405. doi: 10.1210/jc.2009-1082. Epub 2009 Oct 9
[PubMed PMID: 19820010]
[13]
Luo Y, Pan Q, Yao S, Yu M, Wu W, Xue H, Kiesewetter DO, Zhu Z, Li F, Zhao Y, Chen X. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 May:57(5):715-20. doi: 10.2967/jnumed.115.167445. Epub 2016 Jan 21
[PubMed PMID: 26795291]
[14]
Shah R, Garg R, Majmundar M, Purandare N, Malhotra G, Patil V, Ramteke-Jadhav S, Lila A, Shah N, Bandgar T. Exendin-4-based imaging in insulinoma localization: Systematic review and meta-analysis. Clinical endocrinology. 2021 Aug:95(2):354-364. doi: 10.1111/cen.14406. Epub 2021 Jan 21
[PubMed PMID: 33386617]
Level 1 (high-level) evidence
[15]
Imperiale A, Boursier C, Sahakian N, Ouvrard E, Chevalier E, Sebag F, Addeo P, Taïeb D. Value of (68)Ga-DOTATOC and Carbidopa-Assisted (18)F-DOPA PET/CT for Insulinoma Localization. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2022 Mar:63(3):384-388. doi: 10.2967/jnumed.121.262401. Epub 2021 Jul 16
[PubMed PMID: 34272321]
[16]
Murakami T, Fujimoto H, Hamamatsu K, Yamauchi Y, Kodama Y, Fujita N, Fujikura J, Shimizu Y, Nakamoto Y, Kimura H, Saji H, Inagaki N. Distinctive detection of insulinoma using [(18)F]FB(ePEG12)12-exendin-4 PET/CT. Scientific reports. 2021 Jul 22:11(1):15014. doi: 10.1038/s41598-021-94595-6. Epub 2021 Jul 22
[PubMed PMID: 34294854]
[17]
Khashab MA, Yong E, Lennon AM, Shin EJ, Amateau S, Hruban RH, Olino K, Giday S, Fishman EK, Wolfgang CL, Edil BH, Makary M, Canto MI. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointestinal endoscopy. 2011 Apr:73(4):691-6. doi: 10.1016/j.gie.2010.08.030. Epub 2010 Nov 10
[PubMed PMID: 21067742]
[18]
Marx M, Trosic-Ivanisevic T, Caillol F, Demartines N, Schoepfer A, Pesenti C, Ratone JP, Robert M, Giovannini M, Godat S. EUS-guided radiofrequency ablation for pancreatic insulinoma: experience in 2 tertiary centers. Gastrointestinal endoscopy. 2022 Jun:95(6):1256-1263. doi: 10.1016/j.gie.2021.11.045. Epub 2021 Dec 10
[PubMed PMID: 34902374]
[19]
Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT, Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016:103(2):153-71. doi: 10.1159/000443171. Epub 2016 Jan 5
[PubMed PMID: 26742109]
Level 3 (low-level) evidence
[20]
Jonkers YM, Claessen SM, Perren A, Schmitt AM, Hofland LJ, de Herder W, de Krijger RR, Verhofstad AA, Hermus AR, Kummer JA, Skogseid B, Volante M, Voogd AC, Ramaekers FC, Speel EJ. DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients. Endocrine-related cancer. 2007 Sep:14(3):769-79
[PubMed PMID: 17914106]
[21]
Câmara-de-Souza AB,Toyoshima MTK,Giannella ML,Freire DS,Camacho CP,Lourenço DM Jr,Rocha MS,Bacchella T,Jureidini R,Machado MCC,Almeida MQ,Pereira MAA, Insulinoma: A retrospective study analyzing the differences between benign and malignant tumors. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 2018 Apr;
[PubMed PMID: 29452754]
Level 2 (mid-level) evidence
[22]
Kurakawa KI, Okada A, Manaka K, Konishi T, Jo T, Ono S, Uda K, Michihata N, Matsui H, Fushimi K, Yamaguchi S, Yamauchi T, Nangaku M, Yasunaga H, Kadowaki T. Clinical Characteristics and Incidences of Benign and Malignant Insulinoma Using a National Inpatient Database in Japan. The Journal of clinical endocrinology and metabolism. 2021 Nov 19:106(12):3477-3486. doi: 10.1210/clinem/dgab559. Epub
[PubMed PMID: 34343300]
[23]
Sada A, Yamashita TS, Glasgow AE, Habermann EB, Thompson GB, Lyden ML, Dy BM, Halfdanarson TR, Vella A, McKenzie TJ. Comparison of benign and malignant insulinoma. American journal of surgery. 2021 Feb:221(2):437-447. doi: 10.1016/j.amjsurg.2020.08.003. Epub 2020 Aug 16
[PubMed PMID: 32873371]
[24]
Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC, North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May:42(4):557-77. doi: 10.1097/MPA.0b013e31828e34a4. Epub
[PubMed PMID: 23591432]
Level 3 (low-level) evidence
[25]
Su AP, Ke NW, Zhang Y, Liu XB, Hu WM, Tian BL, Zhang ZD. Is laparoscopic approach for pancreatic insulinomas safe? Results of a systematic review and meta-analysis. The Journal of surgical research. 2014 Jan:186(1):126-34. doi: 10.1016/j.jss.2013.07.051. Epub 2013 Aug 19
[PubMed PMID: 23992857]
Level 1 (high-level) evidence
[26]
Gilliaux Q, Bertrand C, Hanon F, Donckier JE. Preoperative treatment of benign insulinoma: diazoxide or somatostatin analogues? Acta chirurgica Belgica. 2022 Apr:122(2):136-139. doi: 10.1080/00015458.2020.1765676. Epub 2020 May 18
[PubMed PMID: 32375590]
[27]
Liang M, Jiang J, Dai H, Hong X, Han X, Cong L, Tong A, Li F, Luo Y, Liu W, Zhou L, Di W, Wu W, Zhao Y. Robotic enucleation for pediatric insulinoma with MEN1 syndrome: a case report and literature review. BMC surgery. 2018 Jun 19:18(1):44. doi: 10.1186/s12893-018-0376-5. Epub 2018 Jun 19
[PubMed PMID: 29921249]
Level 3 (low-level) evidence
[28]
Belfiori G, Wiese D, Partelli S, Wächter S, Maurer E, Crippa S, Falconi M, Bartsch DK. Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. World journal of surgery. 2018 Oct:42(10):3223-3230. doi: 10.1007/s00268-018-4628-4. Epub
[PubMed PMID: 29691623]
[29]
Dąbkowski K, Gajewska P, Walter K, Londzin-Olesik M, Białek A, Andrysiak-Mammos E, Kos-Kudła B, Starzyńska T. Successful EUS-guided ethanol ablation of insulinoma, four-year follow-up. Case report and literature review. Endokrynologia Polska. 2017:68(4):472-479. doi: 10.5603/EP.2017.0053. Epub
[PubMed PMID: 28819950]
Level 3 (low-level) evidence
[30]
Alyusuf EY, Ekhzaimy AA, Rivera JA. Radiofrequency Ablation as a Primary Therapy for Benign Functioning Insulinoma. AACE clinical case reports. 2021 Mar-Apr:7(2):153-157. doi: 10.1016/j.aace.2020.12.003. Epub 2020 Dec 28
[PubMed PMID: 34095476]
Level 3 (low-level) evidence
[31]
Jayawickreme KP, Muthukuda DT, Kariyawasam C, Piyarisi L, Abeywickrama BA. A rare case of insulinoma presenting with deep vein thrombosis, successfully treated with minimally invasive procedures including microwave ablation. Endocrinology, diabetes & metabolism case reports. 2022 May 1:2022():. pii: 21-0127. doi: 10.1530/EDM-21-0127. Epub 2022 May 1
[PubMed PMID: 35510504]
Level 3 (low-level) evidence
[32]
Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgraduate medical journal. 1997 Oct:73(864):640-1
[PubMed PMID: 9497974]
Level 3 (low-level) evidence
[33]
Singh S, Sivajohanathan D, Asmis T, Cho C, Hammad N, Law C, Wong R, Zbuk K. Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline. Current oncology (Toronto, Ont.). 2017 Aug:24(4):249-255. doi: 10.3747/co.24.3634. Epub 2017 Aug 31
[PubMed PMID: 28874893]
Level 1 (high-level) evidence
[34]
Mujica-Mota R, Varley-Campbell J, Tikhonova I, Cooper C, Griffin E, Haasova M, Peters J, Lucherini S, Talens-Bou J, Long L, Sherriff D, Napier M, Ramage J, Hoyle M. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Health technology assessment (Winchester, England). 2018 Sep:22(49):1-326. doi: 10.3310/hta22490. Epub
[PubMed PMID: 30209002]
Level 1 (high-level) evidence
[35]
Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas. 2015 Mar:44(2):181-9. doi: 10.1097/MPA.0000000000000262. Epub
[PubMed PMID: 25479584]
[36]
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. The New England journal of medicine. 2011 Feb 10:364(6):514-23. doi: 10.1056/NEJMoa1009290. Epub
[PubMed PMID: 21306238]
[37]
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England journal of medicine. 2011 Feb 10:364(6):501-13. doi: 10.1056/NEJMoa1003825. Epub
[PubMed PMID: 21306237]
[38]
Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, Hörsch D, Tiensuu Janson E, Ramage J, Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology. 2017:105(3):295-309. doi: 10.1159/000475526. Epub 2017 Apr 13
[PubMed PMID: 28402980]
Level 3 (low-level) evidence
[39]
Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, Willinek W, Biersack HJ, Sabet A. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. European journal of nuclear medicine and molecular imaging. 2014 May:41(5):925-33. doi: 10.1007/s00259-013-2677-3. Epub 2014 Feb 7
[PubMed PMID: 24504504]
[40]
Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O, Sarnelli A, Bodei L, Garaboldi L, Bartolomei M, Paganelli G. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology. 2013:97(4):347-54. doi: 10.1159/000348394. Epub 2013 May 22
[PubMed PMID: 23392072]
[41]
Doi S, Yamada T, Kito Y, Obara S, Fujii Y, Nishimura T, Kato T, Nakayama H, Tsutsumi M, Okamura R. Adult-Onset Focal Nesidioblastosis With Nodular Formation Mimicking Insulinoma. Journal of the Endocrine Society. 2022 Jan 1:6(1):bvab185. doi: 10.1210/jendso/bvab185. Epub 2021 Dec 11
[PubMed PMID: 35024540]
[42]
Luo G,Javed A,Strosberg JR,Jin K,Zhang Y,Liu C,Xu J,Soares K,Weiss MJ,Zheng L,Wolfgang CL,Cives M,Wong J,Wang W,Sun J,Shao C,Wang W,Tan H,Li J,Ni Q,Shen L,Chen M,He J,Chen J,Yu X, Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 20;
[PubMed PMID: 27646952]
[43]
Peltola E, Hannula P, Huhtala H, Metso S, Sand J, Laukkarinen J, Tiikkainen M, Sirén J, Soinio M, Nuutila P, Moilanen L, Laaksonen DE, Ebeling T, Arola J, Schalin-Jäntti C, Jaatinen P. Long-term morbidity and mortality in patients diagnosed with an insulinoma. European journal of endocrinology. 2021 Sep 1:185(4):577-586. doi: 10.1530/EJE-21-0230. Epub 2021 Sep 1
[PubMed PMID: 34374651]